PHAXIAM Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
PHAXIAM Therapeutics has a total shareholder equity of €25.6M and total debt of €13.3M, which brings its debt-to-equity ratio to 51.8%. Its total assets and total liabilities are €51.3M and €25.7M respectively.
Anahtar bilgiler
51.8%
Borç/özkaynak oranı
€13.27m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | €10.47m |
| Eşitlik | €25.61m |
| Toplam yükümlülükler | €25.70m |
| Toplam varlıklar | €51.31m |
Son finansal sağlık güncellemeleri
Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?
Mar 23
ERYTECH Pharma (EPA:ERYP) Has Debt But No Earnings; Should You Worry?
Dec 07
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: PHXM's short term assets (€16.2M) exceed its short term liabilities (€15.3M).
Uzun Vadeli Yükümlülükler: PHXM's short term assets (€16.2M) exceed its long term liabilities (€10.4M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: PHXM's net debt to equity ratio (10.9%) is considered satisfactory.
Borcun Azaltılması: PHXM's debt to equity ratio has increased from 1.4% to 51.8% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: Insufficient data to determine if PHXM has enough cash runway based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if PHXM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.